Patents by Inventor Ryuichiro Nakai
Ryuichiro Nakai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9771351Abstract: A Wnt signaling inhibitor which comprises, as an active ingredient, a fused-ring heterocyclic compound represented by the following formula (IA) or a pharmaceutically acceptable salt thereof, and the like are provided: (wherein, n1A represents 0 or 1; n2A and n3A may be the same or different, and each represents 1 or 2; ROA represents optionally substituted aryl or the like; R2A represents a hydrogen atom or the like; R3A represents an optionally substituted aromatic heterocyclic group or the like; X1A, X2A, X3A and X4A each represent CH or the like; Y1A represents CH2 or the like; Y2A represents N or the like; and LA represents CH2 or the like).Type: GrantFiled: July 29, 2014Date of Patent: September 26, 2017Assignee: KYOWA HAKKO KIRIN CO., LTD.Inventors: Hiroshi Ishida, Keiichi Motosawa, Yusuke Miura, Ryuichiro Nakai, Ryoko Okada, Yuichi Takahashi
-
Publication number: 20160168125Abstract: A Wnt signaling inhibitor which comprises, as an active ingredient, a fused-ring heterocyclic compound represented by the following formula (IA) or a pharmaceutically acceptable salt thereof, and the like are provided: (wherein, n1A represents 0 or 1; n2A and n3A may be the same or different, and each represents 1 or 2; ROA represents optionally substituted aryl or the like; R2A represents a hydrogen atom or the like; R3A represents an optionally substituted aromatic heterocyclic group or the like; X1A, X2A, X3A and X4A each represent CH or the like; Y1A represents CH2 or the like; Y2A represents N or the like; and LA represents CH2 or the like).Type: ApplicationFiled: July 29, 2014Publication date: June 16, 2016Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Hiroshi ISHIDA, Keiichi MOTOSAWA, Yusuke MIURA, Ryuichiro NAKAI, Ryoko OKADA, Yuichi TAKAHASHI
-
Patent number: 7910611Abstract: A therapeutic and/or prophylactic agent for restenosis, which comprises a thiadiazoline derivative represented by the general formula (0), or a pharmaceutically acceptable salt thereof: [wherein, n represents an integer of 1 to 3, R0 represents aryl, —NR1CONR2 (wherein R1 represents a hydrogen atom or the like, and R2 represents lower alkyl or the like) or the like, R3 represents lower alkyl, R4 represents a hydrogen atom or the like, and R5 represents aryl or the like].Type: GrantFiled: June 22, 2006Date of Patent: March 22, 2011Assignees: Kyowa Hakko Kirin Co., Ltd., Fujifilm CorporationInventors: Ryuichiro Nakai, Emi Shimoike, Hideaki Kusaka, Chikara Murakata, Yoshinori Yamashita
-
Patent number: 7902234Abstract: (wherein R1 and R4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R6 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R2 represents —C(?W)R6 or the like; R3 represents a hydrogen atom, —C(?WA)R6A, or the like) Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.Type: GrantFiled: June 2, 2010Date of Patent: March 8, 2011Assignees: Kyowa Hakko Kirin Co., Ltd., Fujifilm CorporationInventors: Chikara Murakata, Kazuhiko Kato, Yoshihisa Ohta, Ryuichiro Nakai, Yoshinori Yamashita, Takeshi Takahashi
-
Publication number: 20110004000Abstract: A mitotic kinesin Eg5 inhibitor which comprises a thiadiazoline derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein R1 represents a hydrogen atom and the like, R2 represents a hydrogen atom, —C(?W)R6 (wherein W represents an oxygen atom or a sulfur atom, and R6 represents substituted or unsubstituted lower alkyl and the like) and the like, R3 represents —C(?Z)R19 (wherein Z represents an oxygen atom or a sulfur atom, and R19 represents substituted or unsubstituted lower alkyl and the like) and the like, R4 represents substituted or unsubstituted lower alkyl and the like, and R5 represents substituted or unsubstituted aryl and the like] and the like are provided.Type: ApplicationFiled: September 16, 2010Publication date: January 6, 2011Applicants: KYOWA HAKKO KIRIN CO., LTD., FUJIFILM CORPORATIONInventors: Chikara MURAKATA, Yoshinori YAMASHITA, Ryuichiro NAKAI, Kazuhito AKASAKA, Yoji INO, Kazuhiko KATO, Yushi KITAMURA
-
Publication number: 20100240716Abstract: (wherein R1 and R4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R6 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R2 represents —C(?W)R4 or the like; R3 represents a hydrogen atom, —C(=WA)R6A, or the like) Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.Type: ApplicationFiled: June 2, 2010Publication date: September 23, 2010Applicants: KYOWA HAKKO KIRIN CO., LTD., FUJIFILM CORPORATIONInventors: Chikara MURAKATA, Kazuhiko KATO, Yoshihisa OHTA, Ryuichiro NAKAI, Yoshinori YAMASHITA, Takeshi TAKAHASHI
-
Patent number: 7759371Abstract: (wherein R1 and R4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R5 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R2 represents —C(?W)R6 or the like; R3 represents a hydrogen atom, —C(?WA)R6A, or the like) Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.Type: GrantFiled: April 7, 2008Date of Patent: July 20, 2010Assignees: Kyowa Hakko Kinn Co., Ltd., FUJIFILM CorporationInventors: Chikara Murakata, Kazuhiko Kato, Yoshihisa Ohta, Ryuichiro Nakai, Yoshinori Yamashita, Takeshi Takahashi
-
Patent number: 7745641Abstract: The present invention provides a nitrogen-containing heterocyclic compound represented by formula (I): {wherein W represents a nitrogen atom or —CH—; X represents —C(?O)— or —CHR4— (wherein R4 represents a hydrogen atom, or the like}; R1 represents a group represented by the following formula: [wherein Q1 represents a nitrogen atom or —CR8— (wherein R8 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like). Q2 represents —NR15— (wherein R15 represents a hydrogen atom, or the like) and R5 and R6 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like]; and R2 and R3 may be the same or different and each represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like} or a pharmaceutically acceptable salt thereof, and the like.Type: GrantFiled: April 19, 2006Date of Patent: June 29, 2010Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Chikara Murakata, Nobuyoshi Amishiro, Toshiyuki Atsumi, Yoshinori Yamashita, Takeshi Takahashi, Ryuichiro Nakai, Hisashi Tagaya, Hiroko Takahashi, Jun Funahashi, Junichiro Yamamoto, Yuichi Fukuda
-
Publication number: 20100029625Abstract: A therapeutic and/or prophylactic agent for restenosis, which comprises a thiadiazoline derivative represented by the general formula (0), or a pharmaceutically acceptable salt thereof: [wherein, n represents an integer of 1 to 3, R0 represents aryl, —NR1CONR2 (wherein R1 represents a hydrogen atom or the like, and R2 represents lower alkyl or the like) or the like, R3 represents lower alkyl, R4 represents a hydrogen atom or the like, and R5 represents aryl or the like].Type: ApplicationFiled: June 22, 2006Publication date: February 4, 2010Applicants: KYOWA HAKKO KIRIN CO., LTD., FUJIFILM CORPORATIONInventors: Ryuichiro Nakai, Emi Shimoike, Hideaki Kusaka, Chikara Murakata, Yoshinori Yamashita
-
Publication number: 20090054407Abstract: The present invention provides a nitrogen-containing heterocyclic compound represented by formula (I): {wherein W represents a nitrogen atom or —CH—; X represents —C(?O)— or —CHR4— (wherein R4 represents a hydrogen atom, or the like); R1 represents a group represented by the following formula: [wherein Q1 represents a nitrogen atom or —CR8— (wherein R8 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like). Q2 represents —NR15— (wherein R15 represents a hydrogen atom, or the like) and R5 and R6 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like]; and R2 and R3 may be the same or different and each represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like} or a pharmaceutically acceptable salt thereof, and the like.Type: ApplicationFiled: April 19, 2006Publication date: February 26, 2009Applicant: Kyowa Hakko Kogyo Co., Ltd.Inventors: Chikara Murakata, Nobuyoshi Amishiro, Toshiyuki Atsumi, Yoshinori Yamashita, Takeshi Takahashi, Ryuichiro Nakai, Hisashi Tagaya, Hiroko Takahashi, Jun Funahashi, Junichiro Yamamoto, Yuichi Fukuda
-
Publication number: 20080262049Abstract: A therapeutic and/or prophylactic agent for a hematopoietic tumor, which comprises a thiadiazoline derivative represented by the general formula (I), or a pharmaceutically acceptable salt thereof: [Formula 1] [wherein, n represents an integer of 1 to 3, R1 represents a hydrogen atom, R2 represents lower alkyl, or R1 and R2 are combined together to represent alkylene, R3 represents lower alkyl, R4 represents NHSO2R6 (wherein R6 represents hydroxy or the like) or the like, and R5 represents aryl or the like] and the like are provided.Type: ApplicationFiled: March 22, 2006Publication date: October 23, 2008Applicants: KYOWA HAKKO KOGYO CO., LTD., FUJIFILM CORPORATIONInventors: Ryuichiro Nakai, Seiho Okamoto, Hideaki Kusaka, Yoshinori Yamashita, Hiroyuki Ishida
-
Patent number: 7425636Abstract: (wherein R1 and R4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R5 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R2 represents —C(?W)R6 or the like; R3 represents a hydrogen atom, —C(?WA)R6A, or the like) Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.Type: GrantFiled: December 11, 2002Date of Patent: September 16, 2008Assignees: Kyowa Hakko Kogyo Co., Ltd., Fuji Photo Film Co., Ltd.Inventors: Chikara Murakata, Kazuhiko Kato, Yoshihisa Ohta, Ryuichiro Nakai, Yoshinori Yamashita, Takeshi Takahashi
-
Publication number: 20080207706Abstract: (wherein R1 and R4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R5 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R2 represents —C(?W)R6 or the like; R3 represents a hydrogen atom, —C(?WA)R6A, or the like) Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.Type: ApplicationFiled: April 7, 2008Publication date: August 28, 2008Applicants: Kyowa Hakko Kogyo Co., Ltd, Fuji Photo Film Co., Ltd.Inventors: Chikara MURAKATA, Kazuhiko Kato, Yoshihisa Ohta, Ryuichiro Nakai, Yoshinori Yamashita, Takeshi Takahashi, Tomohisa Nakano, Yoji Ino
-
Publication number: 20080194653Abstract: A therapeutic and/or prophylactic agent for a solid tumor, which comprises a thiadiazoline derivative represented by the general formula (I), or a pharmaceutically acceptable salt thereof: [wherein, n represents an integer of 1 to 3, R1 represents a hydrogen atom, R2 represents lower alkyl, or R1 and R2 are combined together to represent alkylene, R3 represents lower alkyl, R4 represents NHSO2R6 (wherein R6 represents hydroxy or the like) or the like, and R5 represents aryl or the like] and the like are provided.Type: ApplicationFiled: March 22, 2006Publication date: August 14, 2008Applicants: KYOWA HAKKO KOGYO CO., LTD., FUJIFILM CORPORATIONInventors: Chikara Murakata, Kazuhiko Kato, Junichiro Yamamoto, Ryuichiro Nakai, Seiho Okamoto, Yoji Ino, Yushi Kitamura, Toshikazu Saitoh, Takeshi Katsuhira
-
Publication number: 20070276017Abstract: A thiadiazoline derivative represented by the general formula (I), or a pharmacologically acceptable salt thereof: [wherein R1 represents a hydrogen atom and the like, R2 represents a hydrogen atom, —COR5 (wherein R5 represents lower alkyl and the like) and the like, R3 represents lower alkyl and the like, R4 represents aryl and the like, A represents —(CH2)n— (wherein n represents an integer of 1 to 6) and the like, and B represents —NR6R7 (wherein R6 and R7 are the same or different and represent a hydrogen atom, lower alkyl and the like) and the like] is provided.Type: ApplicationFiled: June 9, 2004Publication date: November 29, 2007Inventors: Chikara Murakata, Yoji Ino, Kazuhiko Kato, Junichiro Yamamoto, Yushi Kitamura, Ryuichiro Nakai, Tomohisa Nakano, Tetsuya Tsujita
-
Publication number: 20070213380Abstract: (wherein R1 and R4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R5 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R2 represents —C(?W)R6 or the like; R3 represents a hydrogen atom, —C(?WA)R6A, or the like) Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.Type: ApplicationFiled: May 11, 2007Publication date: September 13, 2007Applicants: Kyowa Hakko Kogyo Co., Ltd., Fuji Photo Film Co., Ltd.Inventors: Chikara Murakata, Kazuhiko Kato, Yoshihisa Ohta, Ryuichiro Nakai, Yoshinori Yamashita, Takeshi Takahashi, Tomohisa Nakano, Yoji Ino
-
Publication number: 20070155804Abstract: A mitotic kinesin Eg5 inhibitor which comprises a thiadiazoline derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein R1 represents a hydrogen atom and the like, R2 represents a hydrogen atom, —C(?W)R6 (wherein W represents an oxygen atom or a sulfur atom, and R6 represents substituted or unsubstituted lower alkyl and the like) and the like, R3 represents —C(?Z)R19 (wherein Z represents an oxygen atom or a sulfur atom, and R19 represents substituted or unsubstituted lower alkyl and the like) and the like, R4 represents substituted or unsubstituted lower alkyl and the like, and R5 represents substituted or unsubstituted aryl and the like] and the like are provided.Type: ApplicationFiled: April 16, 2004Publication date: July 5, 2007Inventors: Chikara Murakata, Yoshinori Yamashita, Ryuichiro Nakai, Kazuhito Akasaka, Yoji Ino, Kazuhiko Kato, Yushi Kitamura
-
Publication number: 20070112044Abstract: An antitumor agent comprising a thiadiazoline derivative represented by the general formula (I), or a pharmacologically acceptable salt thereof as an active ingredient: (wherein Z represents a sulfur atom and the like, R1 represents substituted or unsubstituted lower alkynyl and the like, R2 represents a hydrogen atom and the like, R3 represents substituted or unsubstituted lower alkyl and the like, and R4 represents substituted or unsubstituted aryl and the like), and the like are provided.Type: ApplicationFiled: October 8, 2004Publication date: May 17, 2007Applicants: Kyowa Hakko Kogyo Co., Ltd., Fuji Photo Film Co., Ltd.Inventors: Chikara Murakata, Nobuyoshi Amishiro, Yoji Ino, Junichiro Yamamoto, Toshiyuki Atsumi, Ryuichiro Nakai, Tomohisa Nakano
-
Publication number: 20060074113Abstract: (wherein R1 and R4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R5 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R2 represents —C(?W)R6 or the like; R3 represents a hydrogen atom, —C(?WA)R6A, or the like) Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.Type: ApplicationFiled: December 11, 2002Publication date: April 6, 2006Inventors: Chikara Murakata, Kazuhiko Kato, Yoshihisa Ohta, Ryuichiro Nakai, Yoshinori Yamashita, Takeshi Takahashi, Tomohisa Nakano, Yoji Ino
-
Patent number: 5965604Abstract: The present invention relates to chrolactomycin compound represented by the following formula (I): ##STR1## or pharmaceutically acceptable salts thereof having antibacterial and antitumor activities.Type: GrantFiled: December 17, 1998Date of Patent: October 12, 1999Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Yoshinori Yamashita, Ryuichiro Nakai, Tamio Mizukami, Shingo Kakita, Shigeru Chiba, Shiro Akinaga